Group 1 - On September 25, Toxin Pharmaceutical experienced a decline of 1.54% with a trading volume of 60.37 million yuan [1] - The financing data on the same day showed a financing purchase amount of 3.99 million yuan and a financing repayment of 7.89 million yuan, resulting in a net financing outflow of 3.89 million yuan [1] - As of September 25, the total balance of margin trading for Toxin Pharmaceutical was 157 million yuan, with a financing balance of 156 million yuan, accounting for 4.02% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of July 31, the number of shareholders for Toxin Pharmaceutical increased by 7.72% to 22,500, while the average circulating shares per person decreased by 7.16% to 4,048 shares [2] - For the first half of 2025, Toxin Pharmaceutical reported an operating income of 182 million yuan, a year-on-year decrease of 16.85%, and a net profit attributable to the parent company of -18.28 million yuan, a significant year-on-year decrease of 927.39% [2] - Since its A-share listing, Toxin Pharmaceutical has distributed a total of 94.64 million yuan in dividends, with 82.04 million yuan distributed over the past three years [2]
拓新药业9月25日获融资买入399.43万元，融资余额1.56亿元